Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment.

× No keyword cloud information.

24 in total

1. Enduring effects of adolescent ketamine exposure on cocaine- and sucrose-induced reward in male and female C57BL/6 mice.

Authors: Israel Garcia-Carachure; Francisco J Flores-Ramirez; Samuel A Castillo; Anapaula Themann; Miguel A Arenivar; Joshua Preciado-Piña; Arturo R Zavala; Mary Kay Lobo; Sergio D Iñiguez
Journal: Neuropsychopharmacology Date: 2020-03-12 Impact factor: 7.853

2. Lucy in the sky with ketamine: Psychoactive drugs have potential for a major breakthrough in treating depression.

Authors: Katrin Weigmann
Journal: EMBO Rep Date: 2018-10-15 Impact factor: 8.807

3. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.

Authors: Nolan R Williams; Boris D Heifets; Christine Blasey; Keith Sudheimer; Jaspreet Pannu; Heather Pankow; Jessica Hawkins; Justin Birnbaum; David M Lyons; Carolyn I Rodriguez; Alan F Schatzberg
Journal: Am J Psychiatry Date: 2018-08-29 Impact factor: 18.112

Review 4. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors: Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal: Behav Brain Res Date: 2020-02-13 Impact factor: 3.332

5. Experimental Therapies for Treatment-Resistant Depression: "How do you decide when to go to an unproven or experimental therapy with patients that are treatment-resistant depression?"

Authors: Manish K Jha; Madhukar H Trivedi
Journal: Focus (Am Psychiatr Publ) Date: 2018-07-18

6. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.

Authors: John Hartberg; Simone Garrett-Walcott; Angelo De Gioannis
Journal: Psychopharmacology (Berl) Date: 2017-11-18 Impact factor: 4.530

7. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.

Authors: Jennifer Swainson; Alexander McGirr; Pierre Blier; Elisa Brietzke; Stéphane Richard-Devantoy; Nisha Ravindran; Jean Blier; Serge Beaulieu; Benicio N Frey; Sidney H Kennedy; Roger S McIntyre; Roumen V Milev; Sagar V Parikh; Ayal Schaffer; Valerie H Taylor; Valérie Tourjman; Michael van Ameringen; Lakshmi N Yatham; Arun V Ravindran; Raymond W Lam
Journal: Can J Psychiatry Date: 2020-11-11 Impact factor: 4.356

Review 8. Medications for substance use disorders (SUD): emerging approaches.

Authors: Eduardo R Butelman; Mary Jeanne Kreek
Journal: Expert Opin Emerg Drugs Date: 2017-10-30 Impact factor: 4.191

9. Sex- and dose-dependent abuse liability of repeated subanesthetic ketamine in rats.

Authors: Kristin J Schoepfer; Caroline E Strong; Samantha K Saland; Katherine N Wright; Mohamed Kabbaj
Journal: Physiol Behav Date: 2017-10-18

Review 10. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.

Authors: Samuel T Wilkinson; Elizabeth D Ballard; Michael H Bloch; Sanjay J Mathew; James W Murrough; Adriana Feder; Peter Sos; Gang Wang; Carlos A Zarate; Gerard Sanacora
Journal: Am J Psychiatry Date: 2017-10-03 Impact factor: 18.112